Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Sunnybrook Health Sciences Centre, Toronto, Canada



Survival: 12.4 months
   
Toxicity Grade: 4
   
Treatments: Immunotherapy
   
Drugs:
Country: Canada
   
City/State/Province: Toronto
   
Hospital: Sunnybrook Health Sciences Centre
   
Journal: Link
   
Date: 9/2012

Description:
Patients:
This phase 2 study involved 40 metastatic melanoma patients who were not previously treated. The median patient age was 56 years and 24 patients were male.

Treatment:
Patients were treated with the immunotherapy agent interleukin 21 (IL-21), which is a cytokine that stimulates the immune system to attack cancer cells.

Toxicities:
The most severe adverse events were grade 4 neutropenia and increased liver enzymes. Grade 3 rash was also reported.

Results:
The median overall survival was 12.4 months. The median progression-free survival was 4.3 months.

Support:
This study was partially supported by ZymoGenetics, which is part of the pharmaceutical company Bristol-Myers Squibb.

Correspondence: Dr. Teresa Petrella; email: teresa.petrella@sunnybrook.ca

E-mail to a Friend Email Physician More Information